首页> 美国卫生研究院文献>Molecular Medicine Reports >RNAi-mediated downregulation of asparaginase-like protein 1 inhibits growth and promotes apoptosis of human cervical cancer line SiHa
【2h】

RNAi-mediated downregulation of asparaginase-like protein 1 inhibits growth and promotes apoptosis of human cervical cancer line SiHa

机译:RNAi介导的天冬酰胺酶样蛋白1下调抑制人宫颈癌SiHa细胞的生长并促进其凋亡

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Asparaginase like 1 (ASRGL1) protein belongs to the N-terminal nucleophile group, cleaving the isoaspartyl-dipeptides and L-asparagine by adding water. It tends to be overexpressed in cancerous tumors including ovarian cancer and breast tumors. The present study assessed the potential ability of ASRGL1 as a molecular target in gene-based cervical cancer treatment. The protein expression level of ASRGL1 was determined in paraffin-embedded tumor specimen by immunohistochemistry. Additionally, in order to assess the activity of ASRGL1 during the process of cervical cancer cell multiplication, ASRGL1-short hairpin (sh) RNA-expressing lentivirus was established, which was used to infect SiHa cells. The Cellomics ArrayScan VT1 Reader identified the influence of downregulation on SiHa caused by RNA interference-intervened ASRGL1. Flow cytometric analysis was also performed to evaluate the influence. The cyclin dependent kinase (CDK2), cyclin A2, B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein (Bax) expression levels were assessed by western blot analysis. ASRGL1 was observed to be overexpressed in cervical cancer tissues when compared with the adjacent normal tissues. The knockdown of ASRGL1 in SiHa by ASRGL1-shRNA lentivirus infection significantly inhibited cell growth and enhanced cellular apoptosis; the cells were also captured during the S phase. The knockdown of ASRGL1 expression led to the increased expression of Bax and decreased expression of Bcl-2, CDK2 and cyclin A2. In conclusion, ASRGL1 was closely associated with growth and apoptosis in cervical cancer. Therefore, ASRGL1 may be a novel, potentially effective anti-cervical cancer therapy.
机译:像1天冬酰胺酶(ASRGL1)蛋白属于N末端亲核基团,通过加水裂解异天冬氨酰二肽和L-天冬酰胺。它倾向于在包括卵巢癌和乳腺肿瘤的癌性肿瘤中过表达。本研究评估了ASRGL1作为基于基因的宫颈癌治疗中的分子靶标的潜在能力。通过免疫组织化学测定石蜡包埋的肿瘤标本中ASRGL1的蛋白表达水平。此外,为了评估ASRGL1在子宫颈癌细胞增殖过程中的活性,建立了表达ASRGL1短发夹(sh)RNA的慢病毒,用于感染SiHa细胞。 Cellomics ArrayScan VT1阅读器确定了RNA干扰ASRGL1引起的SiHa下调的影响。还进行了流式细胞仪分析以评估影响。通过蛋白质印迹分析评估细胞周期蛋白依赖性激酶(CDK2),细胞周期蛋白A2,B细胞淋巴瘤2(Bcl-2)和Bcl-2相关X蛋白(Bax)的表达水平。与邻近的正常组织相比,ASRGL1在宫颈癌组织中过表达。 ASRGL1-shRNA慢病毒感染在SiHa中敲低ASRGL1,可显着抑制细胞生长并增强细胞凋亡。在S期也捕获了细胞。敲低ASRGL1表达导致Bax表达增加而Bcl-2,CDK2和细胞周期蛋白A2减少。总之,ASRGL1与宫颈癌的生长和凋亡密切相关。因此,ASRGL1可能是一种新型的,潜在有效的抗宫颈癌治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号